🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

My first ASCO poster!! What an amazing conference to be a part of - couldn’t be here without the support of my mentors Sam Brondfield, MD, MAEd, FASCO Laura Huppert, MD A Delphi Survey to understand what topics are most important for IM residents to learn about Hem/Onc! Check it out #ASCO24

ISPY2.2 Dato-DXd + durvalumab beautifully presented by Rebecca Shatsky, MD. After 4 cycles neoadj Dato/durva, 4/42 pts w/ HR+ and 21/64 pts w/ HR- stage II/III EBC achieved pCR. 43% pCR in immune+ subtype, meeting graduation threshold. Grateful to participate in this innovate trial & to

Wonderful to spend the evening with this awesome group of fellows and young-faculty — great to meet new colleagues & friends 😀 Kelsey Natsuhara Sarah Premji, MD Charity Huang MD Thomas Grinda Phaedon Zavras Alexis LeVee, MD Targeted Oncology

Beautiful plenary discussion at #MASCC24 about ADC toxicities & management strategies by Hope Rugo! UCSF Helen Diller Family Comprehensive Cancer Ctr

Ellery Altshuler Mark Yarchoan Pashtoon Kasi MD, MS Christina Wu Alexandre Jácome Benjamin Weinberg, MD, FACP Dr. Allyson Ocean @loconte Pamela Kunz, MD, FASCO Arturo LoAIza-Bonilla, MD MSEd @drjasonstarr Sunnie Kim, MD Vivek Subbiah, MD Gaurav Gangwani Shaalan Beg MD MBA FASCO bhawna sirohi Sakti Chakrabarti, MD Aparna Raj Parikh Ben Westphalen @nanudasmd #TumorBoardTuesday 📢And join us in 2 weeks, on 07-23-2024 when Laura Huppert, MD & Kelsey Natsuhara share their insights on Sequencing Therapies in Metastatic #BreastCancer

Latest Bay Area Breast Cancer Forum, moderated by Hope Rugo @ucsfhospitals with UC San Francisco colleagues Michael David Alvarado Laura Huppert, MD Kelsey Natsuhara and more discussed the latest breast cancer research and treatment recommendations presented at #ASCO24 ow.ly/YRa150SBYJl #bcsm

#TumorBoardTuesday I remember when there were so few effective treatments for🧠metastases - but we have come a long way‼️ 📢Join us Tuesday, 07-23-24 at 8PM ET as Laura Huppert, MD & Kelsey Natsuhara🗣️sequencing therapies in #mBC RT and bring others into the discussion‼️

How do you treat #HER2 #breastcancer with 🧠 mets? Join us tomorrow at 8PM for insights on Tx sequencing with Laura Huppert, MD and Kelsey Natsuhara 🌟Let's spark discussions and broaden our understanding together‼️ #TumorBoardTuesday #mBC #BCSM

Nancy Lin, MD presents DESTINY-Breast12: T-DXd in pts w HER2+ w/ & w/o 🧠 metastases, including active BM. 12mo PFS 61.6% overall (stable BM 62.9%; active BM 59.6%) & similar 12mo OS w/ & w/o BM. Supports use of TDXd in pts w/ HER2+ MBC irrespective of stable/active BM

Meghna Trivedi presents data from I-SPY 2 of neoadj Dato-DXd + durvalumab w/ overall pCR 50% (>50% without any chemo & >90% without AC), w/ highest response rate in Immune+ subtype. Love the opportunity to personalize amt of therapy given based on individualize pt response

Katia Khoury gives a beautiful presentation of Dato-DXd x 4 cycles in the ISPY2.2 trial. Exciting data minimizing chemo and tox in a subset of pts with very high risk disease. #ESMO24 OncoAlert

Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! OncoAlert

#ESMO24 Natalee 4 yr update with increasing benefit in all subgroups c/w carryover effect. 36% <3 yrs; 20% due to AEs. 8.6% gr 3+ LFTs AEs. Nitrosamine issue 2b imminently resolved. Exciting advance for mod/hi risk ES HR+ BC. OncoAlert

🎉 Amazing experience attending #ESMO24 with the best UCSF Helen Diller Family Comprehensive Cancer Ctr mentors Hope Rugo Laura Huppert, MD 📍Excited to share our work on T-DXd rechallenge after grade 1 ILD this afternoon at the breast poster session. 👋🏼 Hope to see you at poster 381P!

Kelsey Natsuhara (🌟 UCSF Helen Diller Family Comprehensive Cancer Ctr fellow) presents real-world experience of T-DXd rechallenge after G1 ILD 🫁 - 74% had no recurrent ILD, 26% pts had recurrent ILD but some pts even rechallenged multiple times for G1 w/ ongoing clinical benefit from T-DXd. Hope Rugo #ESMO2024

Grateful for the opportunity to present our research evaluating outcomes with TDXd retreatment after grade 1 ILD at our heme/onc division retreat. Thanks to mentor extraordinaire Hope Rugo and all the amazing UCSF Helen Diller Family Comprehensive Cancer Ctr docs I’m so lucky to work with!

#MedTwitter - Join our Heme/Onc VMR this Monday, March 10th at 4PM PST/7PM EST!🩸 Laura Huppert, MD, Kelsey Natsuhara You won’t want to miss it: bit.ly/31LWIKg

WATCH📺: Alexis LeVee, MD of City of Hope discusses ongoing trials investigating immunotherapy agents and antibody-drug conjugates that may challenge the current SOC for TNBC. Click here for the full video 🔗: onclive.com/view/dr-levee-… #bcsm #oncology

Congrats Kelsey Natsuhara on this excellent multi-center retrospective study of T-DXd rechallenge after grade 1/2 ILD 🫁. Hope Rugo UCSF Helen Diller Family Comprehensive Cancer Ctr 🔹 Rechallenge after grade 1 ILD is safe w/ low rates of ILD recurrence & no G5 events 🔹 Pts remained on T-DXd a median 215 days (!)

Take homes from #ASCO25 rechallenge with tdxd after ild can work; sg first line tnbc; vepdeg me too; inavo impressive in endocrine resistant; dose escalation of abema better; tdxd first line her2 but maybe try maintenance hp; ofs for high risk a must; nk3 for hot flashes #bcsm